[A comparative study of cefepime for chronic respiratory tract infections]
| Autor: | Atsushi SAITO, Yoshiteru SHIGENO, Yuei IRABU, Hiroshi FUKUHARA, Hajime OHSHIRO, Takahiko MIYAKUNI, Jun INATOME, Soukichi ONODERA, Hitoshi NAKANO, Tetsuo SHIMIZU, Nobuhiro SASAKI, Toshiaki FUJIKANE, Yuka FUJITA, Takashi HIROSHIMA, Eiichi SAKAI, Akira SAITO, Yohmei HIRAGA, Mitsuhide OHMICHI, Tsukasa YOSHIDA, Hiromi KANAYAMA, Toshiharu ITO, Tamotsu TAKISHIMA, Yasuo TANNO, Ruriko SATO, Makoto TAKAHASHI, Masaharu SUGIYAMA, Masakichi MOTOMIYA, Akira WATANABE, Yoshihiro HONDA, Yutaka TOKUE, Kazunao NIIZUMA, Shigeo TAKIZAWA, Masataka KATSU, Katsutaka TORIKAI, Susumu SUETSUGU, Shunji YOSHIDA, Kaoru SHIMADA, Yasuyuki SANO, Yasuo ARAI, Takeru KOSHINO, Tetsuhei OGAWA, Yoshio KOBAYASHI, Hiroyuki KOBAYASHI, Takao OKUBO, Hirotada IKEDA, Shigeki ODAGIRI, Masanori MATSUMURA, Yasuhiko ASHIKARI, Yasutsugu AMANO, Akira SHOJI, Takashi SAKUMA, Nobuki AOKI, Kenzo TAKAGI, Kenichi YAMAKI, Kiyoshi SUZUKI, Yasunobu NODA, Hideo GONDA, Toshihiko TAKEUCHI, Johichi KATO, Fumiyuki KUZE, Takako MURAYAMA, Nobuaki IKEDA, Koichi NAKATANI, Kenji BANDO, Souichiro IKEDA, Tadaaki KURODA, Nobuhiro NARITA, Masayoshi SAWAKI, Keiichi MIKASA, Fumio MIKI, Rinzo SOEJIMA, Yoshihito NIKI, Jiro HINO, Masaru SUMI, Toshiharu MATSUSHIMA, Masayoshi KAWANISHI, Makoto KIMURA, Shunkichi HIRAKI, Yohichi WATANABE, Masashi ARAKI, Michiro YAMAKIDO, Kenji HASEGAWA, Takashi TSUYA, Kenichiro SADAMOTO, Masao KUWABARA, Masanobu OKADA, Kenichi ARITA, Masao DOI, Kazuhiro DAIDO, Jitsuro YANAGIDA, Kenichiro WATANABE, Yuichi ATA, Motohiro SUGIHARA, Masato YUKUTAKE, Kouichi AWAYA, Yoshihisa IHARA, Minoru YOSHIDA, Kentaro WATANABE, Takahito HIROSE, Kei SATO, Kohtaro OHIZUMI, Youichiro ICHIKAWA, Masako TANAKA, Kazuma FUJINO, Yoshiyuki MITSUTAKE, Mikio KUBUSHIRO, Toshihiro HIGASHI, Susumu HARADA, Yasuko HARADA, Kohei HARA, Shigeru KOHNO, Hironobu KOGA, Mitsuo KAKU, Keizo MATSUMOTO, Kazunori OHISHI, Hiroshi TANAKA, Kiyoshi SHIMA, Shinobu TAKENAKA, Masaru NASU, Yoichiro GOTO, Tohru YAMAZAKI, Hiroyuki NAGAI, Takayoshi TASHIRO, Nobuya OGAWA, Nobuchika KUSANO |
|---|---|
| Rok vydání: | 1992 |
| Předmět: |
Adult
Male medicine.medical_specialty Adolescent medicine.drug_class Cefepime Cephalosporin Antibiotics Ceftazidime Microbial Sensitivity Tests Internal medicine medicine Potency Humans Respiratory Tract Infections Aged Respiratory tract infections Bacteria business.industry Incidence (epidemiology) Significant difference General Medicine Middle Aged Cephalosporins Chronic Disease Female business medicine.drug |
| Zdroj: | Kansenshogaku zasshi. The Journal of the Japanese Association for Infectious Diseases. 66(7) |
| ISSN: | 0387-5911 |
| Popis: | The clinical efficacy, safety and usefulness of Cefepime (CFPM), a new cephem antibiotics, in chronic respiratory infections were evaluated in a comparative study against Ceftazidime (CAZ). Each drug was administered by intravenous drip infusion at a dose of 1.0 g (nominal potency), twice daily for 14 days, and the following results were obtained: 1. A total of 170 cases were enrolled in this study. Efficacy rates ("good" or better responses) as evaluated by the subcommittee were 86.2% (56/65) in the CFPM group and 84.5% (60/71) in the CAZ group, with no significant difference between the two groups. 2. Efficacy rates ("good" or better responses) as evaluated by attending physicians were 83.3% (55/66) in the CFPM group and 84.5% (60/71) in the CAZ group with no significant difference between the two groups. 3. Bacteriologically, eradication rates were 83.3% (40/48) in the CFPM group and 88.2% (45/51) in the CAZ group, with no significant difference between the two groups. 4. Side effects occurred in none of the patients in the CAZ group and in 4 of the 66 patients in the CFPM group. There was a significant difference between the two groups (Fisher's test p = 0.0489). The incidence of abnormal laboratory findings were 17.6% (12/68) in the CFPM group and 21.1% (16/76) in the CAZ group. There was no significant difference between the two groups. 5. The utility rates evaluated by the subcommittee were 81.8% (54/66) in the CFPM group and 84.5% (60/71) in the CAZ group with no significant difference between the two groups. Only in the incidence of side effects, there was a significant difference between the two groups (Fisher's test p = 0.0489), but there was no significant difference in other items of efficacy, safety and usefulness between the two groups. These results indicate that CFPM is useful for the treatment of chronic respiratory tract infections. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|